CoLabs Medical

Here is a fact that is both well known and, if you sit with it, faintly absurd. More than 500,000 people in the United States go into cardiac arrest every year, and roughly one in ten of them walks out of the hospital neurologically intact. That number has been stubborn for a long time. We have gotten very good at a lot of medicine, and yet the survival math for a heart that suddenly stops has barely moved in a generation. The interesting question is not why the number is bad. The interesting question is which part of the response nobody has bothered to redesign.

CoLabs Medical, a company founded in 2012 and headquartered in Morgan Hill, California, has an answer, and the answer is the breathing. During a cardiac arrest, while chest compressions are happening and drugs are being drawn and a room full of people is moving quickly, someone is usually squeezing a bag - the bag-valve-mask, a device that is essentially a balloon attached to a mask. A human hand decides how fast and how hard. This is, when you describe it plainly, a strange way to run one of the most time-critical procedures in medicine: a life-support function delivered by feel, under stress, by whoever happens to be holding it.

The company's product, The Ventor, is a bet that this step should not be a guess. CoLabs describes it as an integrated emergency airway and ventilation system - and the word doing the work in that sentence is "integrated." The pitch is not that they have built a slightly better bag. The pitch is that airway management during cardiac arrest should be one coherent system rather than a collection of parts handed between people in a chaotic room. It is a product designed less around a feature and more around a workflow, which is a subtle thing to sell and, if it works, a hard thing to compete with.

That framing matters, because the failure mode CoLabs is targeting is not really a technology failure. It is a consistency failure. The tools to ventilate a patient have existed for decades. What varies wildly is how well they get used in the moment - the rate, the volume, the timing, the sheer cognitive load of doing it correctly while everything else is happening. CoLabs' stated mission is to "consistently deliver a new standard of care," and the load-bearing word there is "consistently." The company is essentially arguing that in emergency medicine, reliability is the innovation.

This is where CoLabs gets more interesting than the average medtech startup, because it has refused to do most of the things startups do. It has not pivoted. It has not bolted on a machine-learning story or a wearable or a subscription app. Since 2012 it has worked on approximately one problem, which in the current environment is either admirably disciplined or commercially reckless, and quite possibly both. The homepage carries a line - "Born from experience and designed with passion" - that gestures at the origin story: this is a device that came from someone who watched the problem happen, not from a whiteboard brainstorm about addressable markets.

The refusal to over-claim shows up in the least glamorous place possible, which is the fine print. The Ventor is an investigational device, and CoLabs says so bluntly: "Limited by Federal law to investigational use." You do not build a company for more than a decade and then advertise the thing you have built as not-yet-proven unless you are serious about the difference between hope and evidence. In a category full of companies that describe their prototypes in the present tense, CoLabs describing its device in the conditional is, oddly, a mark of credibility.

The evidence step is now underway. In April 2025, CoLabs began the VENTOR study - a first-in-human clinical trial registered as NCT06759389, running at Stony Brook University Hospital under principal investigator Dr. Jignesh Patel. The design is modest and appropriate for where the device is: a single treatment group, no placebo, enrolling adults in non-traumatic cardiac arrest to evaluate whether the Ventor Airway System can safely provide short-term ventilation during CPR. The company has also said the FDA agreed with its study design, which is the sort of regulatory handshake that does not make headlines but quietly determines whether a device ever reaches a patient outside a trial.

The economics behind all this are worth noting precisely because they are so un-flashy. CoLabs has raised roughly $1.78 million across two rounds, with a Series A that included HealthTech Capital. That is a small number by the standards of splashy device startups, and it has funded a very long runway of careful work rather than a burst of growth. There is a lesson embedded in that figure for founders in life-critical categories: you do not move fast and break things when the thing is a patient. You move carefully, you get the study design right, and you let the timeline be as long as the biology and the regulators require.